Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Castle Biosciences, Inc. - Common stock
(NQ:
CSTL
)
40.01
-0.74 (-1.82%)
Streaming Delayed Price
Updated: 4:00 PM EST, Jan 16, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Castle Biosciences, Inc. - Common stock
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
Traders are paying attention to the gapping stocks in Tuesday's session.
↗
August 05, 2025
Let's have a look at the gap up and gap down stocks in today's session.
Via
Chartmill
These stocks are moving in today's pre-market session
↗
August 05, 2025
The US market is yet to commence its session on Tuesday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
Via
Chartmill
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
↗
August 05, 2025
Via
Benzinga
Earnings Scheduled For August 4, 2025
↗
August 04, 2025
Via
Benzinga
Earnings Scheduled For May 5, 2025
↗
May 05, 2025
Via
Benzinga
Castle (CSTL) Q2 Revenue Tops Estimates
↗
August 04, 2025
Via
The Motley Fool
12 Health Care Stocks Moving In Monday's After-Market Session
↗
August 04, 2025
Via
Benzinga
Castle Biosciences Inc (NASDAQ:CSTL) Surges After Posting Strong Q2 2025 Earnings Beat
↗
August 04, 2025
Castle Biosciences (CSTL) Q2 2025 earnings beat estimates with $86.19M revenue & $0.15 EPS, driving a 6% after-hours surge. Strong test volume growth fuels optimism.
Via
Chartmill
Topics
Earnings
Castle Biosciences Reports Second Quarter 2025 Results
August 04, 2025
From
Castle Biosciences, Inc.
Via
GlobeNewswire
Examining the Future: Castle Biosciences's Earnings Outlook
↗
August 01, 2025
Via
Benzinga
Castle Biosciences to Present at the Canaccord Genuity 45th Annual Growth Conference
July 29, 2025
From
Castle Biosciences, Inc.
Via
GlobeNewswire
Castle Biosciences’ Founder, President and CEO Derek Maetzold Named a Most Admired CEO by the Houston Business Journal
July 25, 2025
The Houston Business Journal's Most Admired CEO Awards recognize chief executive officers who exemplify exceptional leadership, vision and values while guiding Houston's most successful and impactful...
From
Castle Biosciences, Inc.
Via
GlobeNewswire
FDA Grants Breakthrough Device Designation to Castle Biosciences’ DecisionDx®-Melanoma Test
July 23, 2025
From
Castle Biosciences, Inc.
Via
GlobeNewswire
Castle Biosciences Honored with Multiple Top Workplaces Awards Recognizing the Company’s Strong Culture
July 17, 2025
Castle earns recognition as a national Healthcare Industry Top Workplace, an Arizona Top Workplace and receives five Top Workplaces Culture Excellence awards
From
Castle Biosciences, Inc.
Via
GlobeNewswire
Castle Biosciences to Release Second Quarter 2025 Financial Results and Host Conference Call on Monday, Aug. 4, 2025
July 14, 2025
From
Castle Biosciences, Inc.
Via
GlobeNewswire
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 19, 2025
From
Castle Biosciences, Inc.
Via
GlobeNewswire
Castle Biosciences Enters Collaboration and License Agreement with SciBase to Develop Diagnostic Tests for Dermatologic Diseases
June 16, 2025
Initial Development Project Targets Predicting Flares in Patients Diagnosed with Atopic Dermatitis
From
Castle Biosciences, Inc.
Via
GlobeNewswire
Castle Biosciences’ Chief Executive Officer Derek Maetzold to Participate in Panel Discussion During the 2025 BIO International Convention
June 11, 2025
From
Castle Biosciences, Inc.
Via
GlobeNewswire
Castle Biosciences’ Founder, President and CEO Derek Maetzold Honored with Prestigious Lifetime Achievement Award by The American Business Awards®
June 04, 2025
From
Castle Biosciences, Inc.
Via
GlobeNewswire
New Data at ASCO 2025 Affirms DecisionDx®-Melanoma's Ability to Improve Upon Staging-Based Risk Stratification and Predict Survival Outcomes
May 29, 2025
Study results show that DecisionDx-Melanoma was associated with a 32% reduction in mortality risk compared to untested patients
From
Castle Biosciences, Inc.
Via
GlobeNewswire
Castle Biosciences to Present at the 2025 Jefferies Global Healthcare Conference
May 21, 2025
From
Castle Biosciences, Inc.
Via
GlobeNewswire
Real-World Study Confirms Long-Term Performance of DecisionDx®-UM for Metastatic Risk Stratification in Uveal Melanoma and Utility of PRAME Biomarker for Refining Risk When Considered with the DecisionDx-UM Class Result
May 09, 2025
From
Castle Biosciences, Inc.
Via
GlobeNewswire
Castle Biosciences Celebrates Skin Cancer Awareness Month
May 07, 2025
From
Castle Biosciences, Inc.
Via
GlobeNewswire
Nike To $70? Here Are 10 Top Analyst Forecasts For Tuesday
↗
May 06, 2025
Via
Benzinga
Ichor Holdings Posts Weak Earnings, Joins Fabrinet, Vertex Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
↗
May 06, 2025
Via
Benzinga
Castle Biosciences Reports First Quarter 2025 Results
May 05, 2025
From
Castle Biosciences, Inc.
Via
GlobeNewswire
Castle Biosciences to Acquire Previse
May 05, 2025
From
Castle Biosciences, Inc.
Via
GlobeNewswire
New Data at DDW 2025 Further Demonstrates the TissueCypher® Test's Ability to Identify Patients at Increased Risk for Developing Esophageal Cancer
May 02, 2025
From
Castle Biosciences, Inc.
Via
GlobeNewswire
New Study Shows Castle Biosciences’ DecisionDx®-Melanoma Test Outperforms Staging and CP-GEP in Identifying Patients at Low Risk of Sentinel Lymph Node Positivity
April 30, 2025
From
Castle Biosciences, Inc.
Via
GlobeNewswire
DecisionDx®-Melanoma Test Ordered More Than 200,000 Times for Patients Diagnosed with Cutaneous Melanoma
April 28, 2025
From
Castle Biosciences, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
